
  
    
      
        Introduction_NNP
        The_DT clinical_JJ outcome_NN is_VBZ generally_RB positive_JJ for_IN patients_NNS
        with_IN node-negative_JJ breast_NN carcinoma_NN (_( i_NNP ._. e_SYM ._. those_DT patients_NNS
        without_IN detectable_JJ metastases_NNS in_IN the_DT lymph_NN nodes_NNS )_) who_WP have_VBP
        been_VBN treated_VBN with_IN surgery_NN or_CC with_IN surgery_NN and_CC radiation_NN
        therapy_NN ._. The_DT disease_NN spreads_NNS in_IN about_IN 13_CD %_NN of_IN the_DT patients_NNS ,_,
        however_RB ,_, and_CC their_PRP$ lives_NNS are_VBP at_IN risk_NN of_IN death_NN [_NN 1_CD 2_CD 3_CD ]_NN ._.
        Genetic_NNP tests_NNS capable_JJ of_IN identifying_VBG patients_NNS at_IN risk_NN for_IN
        metastatic_JJ spread_NN and_CC /_NN or_CC better_JJR treatment_NN targeted_VBN to_TO
        eradicate_VB metastatic_JJ tumor_NN deposits_NNS could_MD have_VB a_DT dramatic_JJ
        impact_NN on_IN the_DT overall_JJ survival_NN of_IN these_DT patients_NNS ._.
        The_DT construction_NN of_IN a_DT panel_NN of_IN molecular_JJ genetic_JJ markers_NNS
        for_IN identifying_VBG the_DT 13_CD %_NN lymph_NN node-negative_JJ mammary_JJ
        carcinomas_NNS that_WDT are_VBP prone_JJ to_TO develop_VB metastases_NNS [_NN 3_CD ]_NN would_MD
        be_VB valuable_JJ in_IN indicating_VBG those_DT cases_NNS in_IN need_NN of_IN early_JJ
        aggressive_JJ therapy_NN ._. There_EX would_MD also_RB be_VB considerable_JJ
        benefit_NN to_TO the_DT 87_CD %_NN of_IN women_NNS with_IN mammary_JJ carcinomas_NNS who_WP are_VBP
        not_RB likely_JJ to_TO metastasize_NN by_IN sparing_VBG them_PRP the_DT physical_JJ ,_,
        mental_JJ and_CC financial_JJ costs_NNS of_IN the_DT treatment_NN ._. In_IN addition_NN ,_,
        further_JJ knowledge_NN of_IN the_DT genetic_JJ mechanisms_NNS that_WDT play_VBP an_DT
        important_JJ role_NN in_IN metastasis_NNS could_MD ultimately_RB lead_VB to_TO the_DT
        development_NN of_IN improved_VBN therapeutic_JJ procedures_NNS ._.
        The_DT evidence_NN for_IN the_DT role_NN of_IN gene_NN alterations_NNS in_IN
        promoting_VBG metastasis_NNS in_IN general_JJ ,_, and_CC in_IN mammary_JJ carcinomas_NNS
        in_IN particular_JJ ,_, is_VBZ still_RB accumulating_VBG ._. It_PRP is_VBZ probable_JJ ,_,
        however_RB ,_, that_IN like_IN tumorigenicity_NN suppressor_NN genes_NNS and_CC
        oncogenes_NNS many_JJ more_JJR genes_NNS involved_VBN in_IN metastasis_NNS remain_VBP to_TO
        be_VB discovered_VBN since_IN the_DT process_NN is_VBZ complex_JJ ,_, involving_VBG a_DT
        large_JJ number_NN of_IN pathways_NNS [_NN 4_CD ]_NN ._. Most_JJS of_IN the_DT known_VBN genetic_JJ
        mechanisms_NNS involved_VBN in_IN the_DT progression_NN of_IN a_DT tumor_NN to_TO the_DT
        metastatic_JJ state_NN involve_VBP the_DT loss_NN of_IN function_NN of_IN genes_NNS that_WDT
        prevent_VBP cells_NNS from_IN becoming_VBG invasive_JJ ._. These_DT are_VBP similar_JJ to_TO
        tumorigenicity_NN suppressor_NN genes_NNS ,_, whose_WP$ loss_NN of_IN wild-type_JJ
        growth_NN regulatory_JJ function_NN leads_VBZ to_TO unregulated_JJ or_CC
        malignant_JJ growth_NN ._. Similarly_RB ,_, the_DT wild-type_JJ metastasis_NNS
        suppressor_NN genes_NNS regulate_VB the_DT cell_NN 's_POS mobility_NN and_CC its_PRP$
        response_NN to_TO environmental_JJ messages_NNS ,_, presumably_RB keeping_VBG most_JJS
        cells_NNS localized_JJ and_CC differentiated_JJ ._. Mutation_NNP or_CC complete_JJ
        loss_NN (_( deletion_NN )_) of_IN the_DT wild-type_JJ counterpart_NN of_IN any_DT such_JJ
        gene_NN in_IN a_DT malignant_JJ cell_NN may_MD make_VB that_DT cell_NN more_JJR motile_NN ,_,
        invasive_JJ or_CC metastatic_JJ ._. In_IN particular_JJ ,_, mutations_NNS of_IN genes_NNS
        regulating_VBG cell_NN adhesion_NN molecules_NNS have_VBP been_VBN reported_VBN to_TO be_VB
        metastasis-fostering_JJ alterations_NNS [_NN 5_CD 6_CD 7_CD 8_CD ]_NN ._. In_IN human_JJ
        breast_NN cancers_NNS ,_, several_JJ other_JJ genes_NNS have_VBP been_VBN found_VBN to_TO be_VB
        associated_VBN with_IN metastasis_NNS ,_, namely_RB 
        nm_NN 23_CD [_NN 9_CD 10_CD ]_NN ,_, 
        KAI_NNP 1_CD [_NN 11_CD 12_CD ]_NN ,_, 
        mta_NN 1_CD [_NN 13_CD ]_NN ,_, 
        KiSS_NNP 1_CD [_NN 14_CD ]_NN ,_, 
        PTEN_NNP /_NN MMAC_NNP 1_CD [_NN 15_CD 16_CD ]_NN and_CC 
        BRMS_NNP 1_CD [_NN 17_CD ]_NN ._.
        Representational_NNP difference_NN analysis_NN (_( RDA_NNP )_) ,_, a_DT DNA_NNP
        subtractive_JJ hybridization_NN method_NN [_NN 18_CD ]_NN ,_, was_VBD used_VBN in_IN the_DT
        present_JJ study_NN to_TO test_VB the_DT working_VBG hypothesis_NNS that_IN ,_, to_TO
        achieve_VB the_DT metastatic_JJ state_NN ,_, primary_JJ mammary_JJ carcinoma_NN
        cells_NNS must_MD acquire_VB genetic_JJ changes_NNS in_IN addition_NN to_TO those_DT
        changes_NNS that_WDT led_VBD to_TO transformation_NN ._. With_IN the_DT RDA_NNP method_NN ,_,
        DNA_NNP from_IN normal_JJ cells_NNS was_VBD compared_VBN with_IN that_DT of_IN the_DT
        metastatic_JJ cells_NNS of_IN the_DT same_JJ patient_NN ._. The_DT recovered_VBN
        differential_NN sequences_NNS were_VBD then_RB mapped_VBN on_IN human_JJ
        chromosomes_NNS and_CC used_VBN to_TO screen_VB DNA_NNP samples_NNS from_IN normal_JJ ,_,
        primary_JJ and_CC metastatic_JJ cells_NNS of_IN five_CD additional_JJ ductal_NN
        mammary_JJ carcinoma_NN patients_NNS to_TO determine_VB whether_IN these_DT
        sequences_NNS were_VBD consistently_RB associated_VBN with_IN metastasis_NNS ._.
      
      
        Materials_NNS and_CC methods_NNS
        
          Tissue_NNP samples_NNS and_CC cell_NN lines_NNS
          Normal_NNP breast_NN tissue_NN and_CC lymph_NN nodes_NNS with_IN metastatic_JJ
          cells_NNS of_IN a_DT 52_CD -_: year-old_JJ patient_NN (_( C-_NNP 1050_CD )_) with_IN ductal_NN
          mammary_JJ carcinoma_NN were_VBD provided_VBN by_IN the_DT Cooperative_NNP Human_NNP
          Tissue_NNP Network_NNP ._. Additional_JJ matched_VBN normal_JJ ,_, primary_JJ and_CC
          metastatic_JJ tissue_NN samples_NNS were_VBD collected_VBN from_IN four_CD
          patients_NNS (_( patient_NN 1_CD ,_, C-_NNP 18805_CD ;_: patient_NN 2_CD ,_, C-_NNP 98_CD -_: 05_CD H_NNP ;_:
          patient_NN 3_CD ,_, C-_NNP 19898_CD ;_: and_CC patient_NN 4_CD ,_, C-_NNP 20635_CD )_) from_IN the_DT
          Cooperative_NNP Human_NNP Tissue_NNP Network_NNP and_CC from_IN one_CD patient_NN
          (_( patient_NN 5_CD ,_, DS-_NNP 9605_CD )_) from_IN the_DT Surgical_NNP Pathology_NNP
          Department_NNP of_IN Albert_NNP Einstein_NNP College_NNP of_IN Medicine_NNP and_CC
          Montefiore_NNP Medical_NNP Center_NNP ._. The_DT DNA_NNP samples_NNS from_IN mammary_JJ
          carcinoma_NN cell_NN lines_NNS (_( HCC-_NNP 1806_CD ,_, HCC-_NNP 11433_CD ,_, HCC-_NNP 1428_CD and_CC
          HCC-_NNP 1937_CD )_) and_CC matched_VBN normal_JJ cell_NN lines_NNS were_VBD received_VBN
          from_IN Dr_NNP R_NNP Parson_NNP of_IN Columbia_NNP University_NNP ,_, New_NNP York_NNP ,_,
          USA_NNP ._.
        
        
          Isolation_NNP of_IN cells_NNS from_IN biopsy_NN samples_NNS by_IN single_JJ
          cell_NN microdissection_NN
          Single_NNP cell_NN microdissection_NN (_( SCM_NNP )_) was_VBD performed_VBN on_IN
          hematoxylin_NN and_CC eosin-stained_JJ tissue_NN sections_NNS of_IN positive_JJ
          lymph_NN nodes_NNS from_IN the_DT ductal_NN breast_NN cancer_NN patient_NN samples_NNS
          [_NN 19_CD ]_NN ._. In_IN the_DT present_JJ method_NN of_IN SCM_NNP ,_, a_DT Zeiss_NNP axiovert_NN
          phase_NN contrast_NN photomicroscope_NN fitted_JJ with_IN a_DT television_NN
          monitor_NN and_CC a_DT Narashige_NNP mechanical_JJ microdissector_NN was_VBD
          used_VBN ._. A_DT glass_NN micropipette_NN was_VBD used_VBN to_TO draw_VB up_RP individual_JJ
          cells_NNS after_IN dissection_NN ._.
          Tumor_NNP cells_NNS were_VBD identified_VBN in_IN the_DT microscope_NN and_CC ,_,
          using_VBG the_DT tip_NN of_IN a_DT glass_NN micropipette_NN attached_VBN to_TO a_DT
          syringe_NN ,_, they_PRP were_VBD dissected_VBN out_IN without_IN disturbing_VBG the_DT
          surrounding_VBG tissue_NN and_CC were_VBD then_RB drawn_VBN into_IN the_DT pipette_NN ._.
          After_IN five_CD to_TO 10_CD cells_NNS were_VBD collected_VBN in_IN the_DT tip_NN ,_, it_PRP was_VBD
          broken_VBN off_RP and_CC dropped_VBD into_IN a_DT sterile_JJ eppendorf_NN tube_NN ._.
          Approximately_RB 10_CD ,_, 000_CD metastatic_JJ tumor_NN cells_NNS were_VBD
          collected_VBN in_IN this_DT manner_NN for_IN RDA_NNP experiments_NNS ._. The_DT SCM_NNP
          method_NN was_VBD used_VBN to_TO isolate_VB tumor_NN cells_NNS for_IN the_DT RDA_NNP
          experiment_NN because_IN laser-capture_JJ microdissection_NN (_( LCM_NNP )_)
          equipment_NN was_VBD initially_RB not_RB available_JJ ._.
        
        
          Isolation_NNP of_IN cells_NNS from_IN biopsy_NN samples_NNS by_IN
          LCM_NNP
          LCM_NNP [_NN 20_CD ]_NN was_VBD used_VBN for_IN isolating_VBG tumor_NN cells_NNS from_IN
          primary_JJ and_CC metastatic_JJ tissue_NN samples_NNS of_IN additional_JJ
          patients_NNS for_IN screening_NN candidate_NN metastasis-associated_JJ
          DNA_NNP sequences_NNS (_( MADS_NNP )_) by_IN PCR_NNP ._. After_IN many_JJ tumor_NN cells_NNS have_VBP
          been_VBN captured_VBN on_IN the_DT LCM_NNP cap_NN ,_, it_PRP is_VBZ then_RB placed_VBN on_IN a_DT 500_CD
          μl_NN PCR_NNP tube_NN containing_VBG ATL_NNP lysis_NNS buffer_NN (_( Qiagen_NNP Inc_NNP ,_,
          Valencia_NNP ,_, CA_NNP ,_, USA_NNP )_) and_CC the_DT DNA_NNP is_VBZ extracted_VBN ._.
        
        
          DNA_NN extraction_NN
          About_IN 1_CD μg_NN DNA_NNP was_VBD isolated_VBN from_IN approximately_RB 10_CD ,_, 000_CD
          cells_NNS microdissected_JJ from_IN metastatic_JJ tumor_NN and_CC normal_JJ
          (_( glandular_NN and_CC stromal_NN )_) breast_NN tissue_NN samples_NNS ,_, using_VBG a_DT
          modified_VBN method_NN of_IN DNA_NNP extraction_NN from_IN archival_JJ tissues_NNS ._.
          Briefly_NNP ,_, the_DT microdissected_JJ cell_NN pellet_NN was_VBD incubated_JJ
          overnight_JJ in_IN lysis_NNS buffer_NN (_( Qiagen_NNP Inc_NNP )_) with_IN proteinase-_NN K_NNP
          at_IN 55_CD °_NN C_NNP ._. Glycogen_NNP (_( carrier_NN )_) was_VBD added_VBN to_TO the_DT cell_NN lysate_NN
          and_CC DNA_NNP was_VBD extracted_VBN using_VBG a_DT phenol-chloroform-isoamyl_JJ
          alcohol_NN mixture_NN followed_VBN by_IN ethanol_NN precipitation_NN [_NN 19_CD ]_NN
          ._.
        
        
          RDA_NNP and_CC characterization_NN of_IN differential_NN
          products_NNS
          The_DT RDA_NNP procedure_NN was_VBD basically_RB as_IN described_VBN by_IN
          Lisitsyn_NNP and_CC coworkers_NNS [_NN 18_CD 21_CD ]_NN using_VBG the_DT 
          Bgl_NNP II_NNP representation_NN ._. The_DT
          metastatic_JJ cancer_NN cell_NN DNA_NNP was_VBD used_VBN as_IN the_NNP '_POS driver_NN '_'' and_CC
          the_DT DNA_NNP from_IN the_DT normal_JJ cells_NNS was_VBD the_NNP '_POS tester_NN '_'' ._. Three_CD
          rounds_NNS of_IN hybridization_NN were_VBD performed_VBN to_TO subtract_VB the_DT
          common_JJ sequences_NNS ._. The_DT primers_NNS used_VBN for_IN representation_NN and_CC
          hybridization_NN steps_NNS of_IN RDA_NNP are_VBP presented_VBN in_IN Table_NNP 1_CD ._. DNA_NNP
          from_IN the_DT differential_NN bands_NNS (_( lost_VBD in_IN metastasis_NNS )_) was_VBD
          cloned_VBN using_VBG the_DT TA_NNP cloning_VBG system_NN (_( pCR_NN 2_CD ._. 1_LS ;_: Invitrogen_NNP
          Co_NNP ,_, Carlsbad_NNP ,_, CA_NNP ,_, USA_NNP )_) ._. Clones_NNP were_VBD selected_VBN at_IN random_JJ
          and_CC used_VBN as_IN α_NN 32_CD P-_NNP dCTP_NN (_( Amersham_NNP Biosciences_NNP Corp_NNP ,_,
          Piscataway_NNP ,_, NY_NNP ,_, USA_NNP )_) probes_NNS on_IN dot_VBP blots_NNS or_CC Southern_NNP
          blots_NNS containing_VBG amplicon_NN DNA_NNP from_IN the_DT original_JJ normal_JJ
          and_CC metastatic_JJ cells_NNS to_TO verify_VB whether_IN these_DT sequences_NNS
          are_VBP actually_RB present_JJ in_IN the_DT normal_JJ cell_NN DNA_NNP sample_NN and_CC
          missing_VBG in_IN the_DT metastatic_JJ cell_NN DNA_NNP samples_NNS ._. Positive_JJ
          clones_NNS (_( showing_VBG signals_NNS in_IN normal_JJ cell_NN DNA_NNP and_CC missing_VBG in_IN
          metastatic_JJ cell_NN DNA_NNP )_) were_VBD sequenced_JJ ._. A_DT homology_NN search_NN
          was_VBD performed_VBN using_VBG the_DT National_NNP Center_NNP for_IN Biotechnology_NNP
          Information_NNP ,_, National_NNP Institutes_NNPS for_IN Health_NNP ,_, USA_NNP (_( NCBI_NNP )_)
          Blast_NNP program_NN and_CC physical_JJ mapping_NN ._.
        
        
          Radiation_NNP hybrid_JJ mapping_NN
          Radiation_NNP hybrid_JJ mapping_NN was_VBD used_VBN to_TO localize_NN the_DT MADS_NNP
          on_IN human_JJ chromosomes_NNS using_VBG high-resolution_JJ Gene-_NNP Bridge_NNP 4_CD
          radiation_NN hybrid_JJ panels_NNS (_( Research_NNP Genetics_NNP ,_, Inc_NNP ,_,
          Carlsbad_NNP ,_, CA_NNP ,_, USA_NNP )_) ._. Based_VBN on_IN the_DT sequences_NNS of_IN
          differential_NN products_NNS isolated_VBN from_IN RDA_NNP experiments_NNS ,_, 10_CD
          pairs_NNS of_IN PCR_NNP primers_NNS were_VBD designed_VBN for_IN 10_CD groups_NNS of_IN
          candidate_NN gene_NN sequences_NNS ._. Based_VBN on_IN the_DT PCR_NNP results_NNS ,_,
          chromosome_NN localization_NN of_IN these_DT sequences_NNS was_VBD determined_VBN
          using_VBG the_DT Whitehead_NNP Institute_NNP /_NN MIT_NNP databases_NNS [_NN 22_CD ]_NN ._.
        
        
          Fluorescence_NNP in_IN situhybridization_NN of_IN MADS-IX_NNP
          Chromosome_NNP preparations_NNS were_VBD made_VBN from_IN
          phytohemagglutinin-stimulated_JJ peripheral_JJ blood_NN lymphocyte_NN
          cultures_NNS from_IN normal_JJ individuals_NNS ._. The_DT slides_NNS were_VBD fixed_VBN
          in_IN methanol-acetic_JJ acid_NN and_CC were_VBD air-dried_JJ ._. The_DT probes_NNS
          used_VBN for_IN fluorescence_NN 
          in_IN situ_NN hybridization_NN (_( FISH_NNP )_) were_VBD
          the_DT Spectrum_NNP Green_NNP labeled_VBD centromere_NN of_IN 8_CD (_( Vysis_NNP ,_,
          Downers_NNP Grove_NNP ,_, IL_NNP ,_, USA_NNP )_) and_CC the_DT Spectrum_NNP Green_NNP labeled_VBD 2_CD
          kb_NN sized_VBD MADS-IX_NNP sequence_NN ._. Primers_NNP were_VBD designed_VBN from_IN the_DT
          BAC_NNP clone_NN (_( NCBI_NNP ,_, NIH_NNP ,_, USA_NNP ,_, RP_NNP 11_CD -_: 407_CD )_) containing_VBG the_DT
          MADS-IX_NNP sequence_NN to_TO obtain_VB a_DT 2_CD kb_NN sized_VBD PCR_NNP product_NN
          encompassing_VBG the_DT MADS-IX_NNP region_NN (_( Table_NNP 1_LS )_) ._.
          The_DT 2_CD kb_NN DNA_NNP fragment_NN was_VBD run_VBN on_IN a_DT 1_CD %_NN gel_NN ,_, isolated_VBN
          from_IN gel_NN and_CC eluted_JJ in_IN water_NN ,_, and_CC was_VBD labeled_VBN with_IN
          Spectrum_NNP Green_NNP using_VBG the_DT nick_NN translation_NN method_NN ,_,
          following_VBG the_DT manufacturer_NN 's_POS instructions_NNS (_( Vysis_NNP )_) ._.
          Three-day-old_NNP slides_NNS were_VBD denatured_JJ in_IN 70_CD %_NN formamide_NN /_NN 2_CD ×_NN
          SSC_NNP (_( sodium_NN citrate_NN /_NN chloride_NN )_) solution_NN at_IN 74_CD °_NN C_NNP ._. The_DT
          dehydrated_JJ and_CC air-dried_JJ slides_NNS were_VBD used_VBN for_IN
          hybridization_NN according_VBG to_TO published_VBN methods_NNS with_IN some_DT
          modifications_NNS [_NN 23_CD 24_CD ]_NN ._. The_DT slides_NNS were_VBD counter-stained_JJ
          with_IN 4_CD ,_, 6_CD -_: diamidino-_NN 2_CD -_: phenylindole_NN dihydrochloride_NN
          (_( Molecular_NNP Probes_NNP ,_, Eugene_NNP ,_, OR_NNP ,_, USA_NNP )_) and_CC images_NNS were_VBD
          captured_VBN on_IN the_DT Nikon_NNP E_NNP 800_CD using_VBG the_DT Quips_VBZ Pathvysion_NNP
          system_NN (_( Applied_NNP Imaging_NNP ,_, Santa_NNP Clara_NNP ,_, CA_NNP ,_, USA_NNP )_) ._.
        
      
      
        Results_NNS
        
          Isolation_NNP of_IN candidate_NN MADS_NNP
          RDA_NNP was_VBD performed_VBN with_IN the_DT DNA_NNP recovered_VBN by_IN SCM_NNP from_IN
          normal_JJ cells_NNS and_CC from_IN metastatic_JJ cells_NNS in_IN the_DT lymph_NN nodes_NNS
          of_IN a_DT patient_NN with_IN ductal_NN mammary_JJ carcinoma_NN ._. Since_IN the_DT
          objective_NN was_VBD to_TO isolate_VB sequences_NNS that_WDT are_VBP lost_VBN in_IN the_DT
          progression_NN of_IN cells_NNS from_IN normal_JJ to_TO metastasis_NNS ,_, we_PRP
          focused_VBD on_IN the_DT products_NNS of_IN RDA_NNP in_IN which_WDT the_DT metastatic_JJ
          cell_NN DNA_NNP was_VBD used_VBN as_IN the_DT driver_NN and_CC the_DT normal_JJ cell_NN DNA_NNP
          was_VBD the_DT tester_NN ._.
          As_IN shown_VBN in_IN Fig_NNP ._. 1_LS ,_, RDA_NNP differential_NN products_NNS were_VBD
          isolated_VBN and_CC DNA_NNP was_VBD extracted_VBN from_IN each_DT of_IN the_DT five_CD
          bands_NNS obtained_VBN from_IN the_DT loss_NN side_NN of_IN the_DT third_JJ round_NN of_IN
          hybridization_NN ,_, and_CC DNA_NNP from_IN each_DT band_NN was_VBD cloned_VBN
          separately_RB ._. One_CD hundred_CD clones_NNS from_IN each_DT DNA_NNP band_NN were_VBD
          saved_VBN and_CC a_DT subset_NN of_IN 100_CD clones_NNS (_( 20_CD clones_NNS from_IN each_DT
          differential_NN product_NN )_) was_VBD selected_VBN randomly_RB for_IN further_JJ
          characterization_NN ._. These_DT 100_CD clones_NNS were_VBD probed_JJ (_( labeled_VBN
          with_IN α_NN 32_CD P-_NNP dCTP_NN )_) on_IN dot_VBP blots_NNS containing_VBG normal_JJ cell_NN DNA_NNP
          and_CC metastatic_JJ cell_NN DNA_NNP ._. It_PRP was_VBD found_VBN that_IN 79_CD clones_NNS
          hybridized_JJ only_RB with_IN the_DT normal_JJ cell_NN DNA_NNP and_CC did_VBD not_RB
          hybridize_NN with_IN DNA_NNP from_IN the_DT metastatic_JJ cells_NNS (_( Fig_NNP ._. 2_LS a_DT )_) ._.
          The_DT remaining_VBG clones_NNS hybridized_JJ with_IN both_DT normal_JJ cell_NN DNA_NNP
          and_CC the_DT metastatic_JJ cell_NN DNA_NNP ._. This_DT may_MD have_VB been_VBN due_JJ to_TO
          incomplete_JJ subtraction_NN ._. Of_IN the_DT 79_CD clones_NNS that_IN hybridized_JJ
          only_RB with_IN the_DT DNA_NNP of_IN the_DT normal_JJ cells_NNS ,_, 50_CD were_VBD selected_VBN
          and_CC tested_VBN further_RB by_IN Southern_NNP blotting_VBG to_TO verify_VB the_DT RDA_NNP
          results_NNS ._. None_NN of_IN these_DT clones_NNS hybridized_JJ with_IN the_DT DNA_NNP of_IN
          the_DT metastatic_JJ cells_NNS ,_, and_CC all_DT were_VBD detected_VBN in_IN normal_JJ
          cells_NNS (_( Fig_NNP ._. 2_LS b_SYM )_) ._.
        
        
          Sequencing_NNP and_CC homology_NN search_NN of_IN candidate_NN
          MADS_NNP
          RDA_NNP derived_VBD 50_CD clones_NNS that_WDT were_VBD sequenced_JJ and_CC those_DT
          with_IN identical_JJ sequences_NNS were_VBD grouped_VBN ._. Ten_CD unique_JJ
          candidate_NN MADS_NNP were_VBD thus_RB identified_VBN ._. The_DT sequence_NN
          homologies_NNS found_VBN by_IN searching_VBG the_DT nucleotide_NN databases_NNS of_IN
          these_DT MADS_NNP are_VBP presented_VBN in_IN Table_NNP 2_CD ._. The_DT search_NN revealed_VBD
          that_IN these_DT MADS_NNP have_VBP homology_NN with_IN sequences_NNS on_IN
          chromosome_NN 1_CD (_( MADS-III_NNP )_) ,_, chromosome_NN 5_CD (_( MADS-I_NNP )_) ,_,
          chromosome_NN 6_CD (_( MADS-VII_NNP and_CC MADS-VIII_NNP )_) ,_, chromosome_NN 7_CD
          (_( MADS-VI_NNP )_) ,_, chromosome_NN 10_CD (_( MADS-IX_NNP )_) ,_, chromosome_NN 15_CD
          (_( MADS-X_NNP )_) ,_, chromosome_NN 16_CD (_( MADS-V_NNP )_) and_CC chromosome_NN 21_CD
          (_( MADS-II_NNP )_) ._. Nine_CD of_IN these_DT MADS_NNP have_VBP about_IN 82_CD -_: 99_CD %_NN homology_NN
          to_TO known_VBN human_JJ DNA_NNP sequences_NNS ,_, and_CC the_DT remaining_VBG MADS-IV_NNP
          was_VBD found_VBN to_TO be_VB novel_NN ,_, having_VBG no_DT homology_NN with_IN the_DT
          sequences_NNS in_IN the_DT gene_NN banks_NNS ._.
        
        
          Radiation_NNP hybrid_JJ mapping_NN of_IN MADS_NNP
          We_PRP used_VBD the_DT GeneBridge_NNP 4_CD Radiation_NNP Hybrid_NNP panel_NN
          (_( Research_NNP Genetics_NNP ,_, Inc_NNP )_) to_TO localize_NN these_DT 10_CD MADS_NNP on_IN
          human_JJ chromosomes_NNS ._. For_IN this_DT physical_JJ mapping_NN ,_, and_CC also_RB to_TO
          be_VB able_JJ to_TO use_VB these_DT sequences_NNS to_TO screen_VB additional_JJ
          patient_NN samples_NNS ,_, primer_NN pairs_NNS were_VBD designed_VBN for_IN each_DT
          sequence_NN and_CC tested_VBN by_IN PCR_NNP on_IN a_DT positive_JJ control_NN (_( human_JJ
          genomic_JJ DNA_NNP )_) and_CC on_IN two_CD negative_JJ controls_NNS (_( Chinese_JJ
          hamster_NN genomic_JJ DNA_NNP and_CC no_DT template_NN )_) ._. Of_IN the_DT 10_CD MADS_NNP
          tested_VBD ,_, only_RB five_CD (_( MADS-IV_NNP ,_, MADS-VII_NNP ,_, MADS-VIII_NNP ,_, MADS-IX_NNP
          and_CC MADS-X_NNP )_) were_VBD successfully_RB mapped_VBN to_TO specific_JJ human_JJ
          chromosomes_NNS (_( Table_NNP 2_LS )_) ._. Of_IN these_DT five_CD MADS_NNP ,_, MADS-IV_NNP did_VBD
          not_RB show_VB any_DT match_NN with_IN gene_NN bank_NN sequences_NNS and_CC therefore_RB
          appeared_VBD to_TO be_VB a_DT novel_JJ DNA_NNP sequence_NN ._. The_DT chromosome_NN
          localizations_NNS for_IN MADS-VII_NNP ,_, MADS-VIII_NNP ,_, MADS-IX_NNP and_CC MADS-X_NNP
          obtained_VBN by_IN physical_JJ mapping_NN and_CC by_IN homology_NN search_NN data_NNS
          were_VBD in_IN agreement_NN ._.
        
        
          Further_RB characterization_NN of_IN MADS-IX_NNP
          While_IN the_DT homology_NN results_NNS of_IN MADS-IX_NNP revealed_VBD that_IN it_PRP
          has_VBZ 94_CD %_NN homology_NN with_IN the_DT sequence_NN on_IN chromosome_NN 10_CD q_NN
          (_( BAC-AC_NNP 022541_CD ._. 10_CD )_) ,_, the_DT radiation_NN hybrid_JJ mapping_NN showed_VBD
          that_IN MADS-IX_NNP is_VBZ localized_VBN to_TO a_DT 21_CD cR_NN interval_NN between_IN
          markers_NNS D_NNP 105539_CD and_CC D_NNP 10_CD S_NNP 549_CD ,_, corresponding_JJ to_TO human_JJ
          chromosome_NN 10_CD band_NN q_NN 21_CD ._. 1_LS [_NN 25_CD ]_NN ._. To_TO confirm_VB that_IN MADS-IX_NNP
          is_VBZ not_RB an_DT artifact_NN and_CC is_VBZ actually_RB a_DT human_JJ DNA_NNP sequence_NN
          located_VBN on_IN chromosome_NN 10_CD q_NN ,_, we_PRP used_VBD the_DT sequence_NN as_IN a_DT
          fluorescence_NN 
          in_IN situ_NN hybridization_NN probe_NN on_IN
          human_JJ metaphase_NN chromosomes_NNS ._. Based_VBN on_IN the_DT sequence_NN of_IN the_DT
          BAC_NNP clone_NN (_( NCBI_NNP ,_, RP_NNP 11_CD -_: 407_CD )_) encompassing_VBG MADS-IX_NNP ,_, a_DT 2_CD kb_NN
          DNA_NNP fragment_NN containing_VBG MADS-IX_NNP was_VBD generated_VBN by_IN PCR_NNP ._. To_TO
          localize_NN MADS-IX_NNP cytologically_RB ,_, we_PRP labeled_VBD the_DT 2_CD kb_NN sized_VBD
          MADS-IX_NNP with_IN Spectrum_NNP Green_NNP (_( Vysis_NNP )_) and_CC hybridized_JJ on_IN
          normal_JJ human_JJ metaphase_NN chromosomes_NNS ._. Figure_NN 3_CD shows_VBZ that_IN
          the_DT MADS-IX_NNP probe_NN was_VBD hybridized_JJ on_IN the_DT 10_CD q_NN 21_CD region_NN ._. The_DT
          Spectrum_NNP Green_NNP labeled_VBD centromere_NN of_IN chromosome_NN 8_CD (_( Vysis_NNP )_)
          was_VBD used_VBN as_IN a_DT control_NN ._.
          To_TO determine_VB whether_IN MADS-IX_NNP is_VBZ indeed_RB associated_VBN with_IN
          metastasis_NNS ,_, DNA_NNP was_VBD screened_VBD from_IN cells_NNS recovered_VBD with_IN
          the_DT LCM_NNP method_NN from_IN normal_JJ ,_, primary_JJ and_CC metastatic_JJ tissue_NN
          samples_NNS from_IN five_CD additional_JJ patients_NNS ._. Because_IN MADS-IX_NNP
          was_VBD mapped_VBN to_TO chromosome_NN 10_CD q_NN 21_CD ,_, we_PRP also_RB wanted_VBD to_TO
          determine_VB whether_IN it_PRP was_VBD located_VBN in_IN the_DT region_NN
          encompassing_VBG a_DT well-known_JJ metastasis-associated_JJ gene_NN ,_, 
          PTEN_NNP [_NN 15_CD ]_NN ._.
          First_LS ,_, DNA_NNP samples_NNS from_IN these_DT five_CD patients_NNS were_VBD
          screened_VBD by_IN PCR_NNP using_VBG primers_NNS designed_VBN for_IN MADS-IX_NNP and_CC 
          PTEN_NNP ._. MADS-IX_NNP showed_VBD PCR_NNP
          amplification_NN in_IN normal_JJ cell_NN DNA_NNP samples_NNS of_IN all_PDT the_DT five_CD
          patients_NNS ,_, but_CC the_DT intensities_NNS of_IN the_DT PCR_NNP bands_NNS were_VBD less_JJR
          in_IN the_DT primary_JJ tumor_NN cell_NN DNA_NNP samples_NNS and_CC were_VBD totally_RB
          undetectable_JJ in_IN the_DT metastatic_JJ cell_NN DNA_NNP of_IN patients_NNS 1_CD and_CC
          3_CD (_( Fig_NNP ._. 4_LS )_) ._. The_DT 
          PTEN_NNP gene_NN ,_, on_IN the_DT contrary_NN ,_, was_VBD
          detected_VBN ,_, without_IN any_DT difference_NN in_IN the_DT intensity_NN of_IN PCR_NNP
          bands_NNS in_IN the_DT DNA_NNP samples_NNS of_IN normal_JJ cells_NNS ,_, primary_JJ tumor_NN
          cells_NNS and_CC metastatic_JJ lymph_NN node_NN cells_NNS of_IN all_DT five_CD
          patients_NNS ._.
          Second_JJ ,_, MADS-IX_NNP and_CC 
          PTEN_NNP were_VBD screened_VBD in_IN four_CD breast_NN
          tumor_NN cell_NN lines_NNS (_( HCC-_NNP 1806_CD ,_, HCC-_NNP 1143_CD ,_, HCC-_NNP 1428_CD and_CC
          HCC-_NNP 1937_CD )_) and_CC matched_VBN normal_JJ DNA_NNP ._. The_DT first_JJ three_CD tumor_NN
          cell_NN lines_NNS had_VBD known_JJ losses_NNS in_IN specific_JJ chromosomal_NN
          regions_NNS ,_, and_CC the_DT fourth_RB had_VBD loss_NN of_IN homozygosity_NN of_IN the_DT 
          PTEN_NNP gene_NN ._. PCR_NNP screening_NN of_IN MADS-IX_NNP
          and_CC 
          PTEN_NNP showed_VBD that_IN MADS-IX_NNP is_VBZ present_JJ
          in_IN all_DT four_CD tumor_NN cell_NN lines_NNS ,_, but_CC 
          PTEN_NNP is_VBZ only_RB present_JJ in_IN cell_NN lines_NNS
          HCC-_NNP 1806_CD ,_, HCC-_NNP 1143_CD and_CC HCC-_NNP 1428_CD and_CC is_VBZ missing_VBG in_IN
          HCC-_NNP 1937_CD (_( Fig_NNP ._. 5_LS )_) ._.
        
      
      
        Discussion_NNP
        Reports_NNS show_VBP a_DT statistically_RB significant_JJ increase_NN in_IN
        loss_NN of_IN heterozygosity_NN events_NNS involving_VBG unknown_JJ genes_NNS on_IN
        chromosome_NN 16_CD q_NN [_NN 26_CD ]_NN ,_, on_IN chromosome_NN 10_CD q_NN [_NN 15_CD ]_NN and_CC on_IN
        chromosome_NN 14_CD q_NN [_NN 27_CD ]_NN ,_, in_IN metastatic_JJ breast_NN cancers_NNS ._.
        Measuring_NN loss_NN of_IN heterozygosity_NN ,_, O_NNP '_POS Connell_NNP 
        et_CC al_NN ._. [_NN 27_CD ]_NN found_VBD that_IN the_DT
        majority_NN of_IN lymph_NN node-negative_JJ primary_JJ breast_NN tumors_NNS did_VBD
        not_RB amplify_VB a_DT region_NN linked_VBN to_TO D_NNP 14_CD S_NNP 62_CD and_CC D_NNP 14_CD S_NNP 51_CD ,_, while_IN
        lymph_NN node-positive_JJ breast_NN tumors_NNS retained_VBD heterozygosity_NN
        for_IN these_DT markers_NNS ._. These_DT data_NNS could_MD imply_VB the_DT existence_NN of_IN
        metastasis_NNS promoting_VBG gene_NN (_( s_VBZ )_) in_IN that_DT region_NN or_CC ,_,
        alternatively_RB ,_, the_DT observed_VBD molecular_JJ changes_NNS may_MD be_VB used_VBN
        as_IN a_DT marker_NN of_IN metastatic_JJ propensity_NN [_NN 28_CD ]_NN ._.
        In_IN the_DT present_JJ investigation_NN we_PRP used_VBD RDA_NNP in_IN an_DT attempt_NN
        to_TO identify_VB genetic_JJ alterations_NNS related_VBN to_TO breast_NN cancer_NN
        metastasis_NNS by_IN comparing_VBG normal_JJ cell_NN DNA_NNP and_CC metastatic_JJ cell_NN
        DNA_NNP of_IN a_DT ductal_NN breast_NN carcinoma_NN patient_NN ._. Ten_CD unique_JJ
        candidate_NN MADS_NNP were_VBD identified_VBN and_CC the_DT sequence_NN homologies_NNS
        found_VBN by_IN searching_VBG the_DT gene_NN bank_NN of_IN these_DT MADS_NNP are_VBP
        presented_VBN in_IN Table_NNP 2_CD ._. The_DT search_NN revealed_VBD 82_CD -_: 99_CD %_NN homology_NN
        to_TO known_VBN human_JJ gene_NN sequences_NNS for_IN nine_CD of_IN these_DT MADS_NNP but_CC
        MADS-IV_NNP was_VBD found_VBN to_TO be_VB novel_NN ,_, having_VBG no_DT homology_NN with_IN the_DT
        sequences_NNS in_IN the_DT gene_NN banks_NNS ._. Further_RB characterization_NN of_IN
        MADS-IX_NNP revealed_VBD interesting_JJ information_NN on_IN the_DT genes_NNS and_CC
        sequence_NN tagged_VBN sites_NNS (_( STS_NNP )_) markers_NNS surrounding_VBG it_PRP ._. Within_IN
        a_DT range_NN of_IN 1_CD ._. 4_CD Mb_NNP of_IN MADS-IX_NNP ,_, we_PRP noticed_VBD two_CD 
        CDC_NNP 2_CD genes_NNS (_( cell_NN division_NN cycle_NN 2_CD
        protein_NN ,_, isoform_NN 1_CD and_CC isoform_NN 2_LS )_) and_CC two_CD splice_NN variants_NNS
        of_IN the_DT 
        ZWINT_NNP gene_NN (_( without_IN known_VBN exact_JJ
        function_NN )_) ._. In_IN the_DT range_NN of_IN 821_CD kb_NN ,_, there_EX are_VBP nine_CD STS_NNP
        markers_NNS (_( RH_NNP 26942_CD ,_, SHGC-_NNP 58267_CD ,_, SHGC-_NNP 79901_CD ,_, AFM_NNP 336_CD XD_NNP 1_CD ,_,
        SHGC-_NNP 103705_CD ,_, SHGC-_NNP 3856_CD ,_, SHGC-_NNP 84937_CD ,_, STSG_NNP 72171_CD and_CC
        SHGC-_NNP 81245_CD )_) ._.
        Physical_NNP and_CC cytological_JJ mapping_NN of_IN MADS-IX_NNP confirmed_VBD
        that_IN it_PRP is_VBZ located_VBN at_IN 10_CD q_NN 21_CD ._. 1_LS ._. Screening_NNP of_IN MADS-IX_NNP on_IN DNA_NNP
        samples_NNS from_IN five_CD more_JJR sets_NNS of_IN normal_JJ ,_, primary_JJ and_CC matched_VBN
        metastatic_JJ tumor_NN samples_NNS (_( Fig_NNP ._. 4_LS )_) revealed_VBD that_IN MADS-IX_NNP is_VBZ
        lost_VBN in_IN the_DT transition_NN from_IN normal_JJ cells_NNS to_TO primary_JJ cells_NNS
        to_TO metastasis_NNS cells_NNS in_IN two_CD of_IN five_CD cases_NNS (_( three_CD of_IN six_CD
        cases_NNS if_IN the_DT case_NN used_VBN in_IN the_DT RDA_NNP assay_NN is_VBZ included_VBN )_) ._. PCR_NNP
        screening_NN of_IN 
        PTEN_NNP on_IN these_DT five_CD patient_NN samples_NNS
        and_CC screening_NN of_IN MADS-IX_NNP and_CC 
        PTEN_NNP on_IN a_DT breast_NN carcinoma_NN cell_NN line_NN
        that_WDT had_VBD loss_NN of_IN homozygosity_NN of_IN the_DT 
        PTEN_NNP gene_NN revealed_VBD that_IN MADS-IX_NNP is_VBZ
        neither_DT a_DT part_NN of_IN the_DT 
        PTEN_NNP gene_NN or_CC localized_JJ in_IN the_DT
        homozygous_JJ loss_NN region_NN of_IN chromosome_NN 10_CD q_NN encompassing_VBG the_DT 
        PTEN_NNP gene_NN ._. These_DT findings_NNS together_RB
        strongly_RB suggest_VBP that_IN MADS-IX_NNP is_VBZ a_DT candidate_NN marker_NN for_IN a_DT
        novel_NN metastasis_NNS suppressor_NN gene_NN ._. Additional_JJ archival_JJ cases_NNS
        are_VBP being_VBG screened_VBD to_TO determine_VB whether_IN MADS-IX_NNP is_VBZ a_DT
        reliable_JJ marker_NN for_IN metastasis_NNS in_IN ductal_NN breast_NN
        cancers_NNS ._.
      
      
        Competing_VBG interests_NNS
        None_NN declared_VBD ._.
      
      
        Abbreviations_NNP
        bp_NN =_SYM base_NN pairs_NNS ;_: FISH_NNP =_SYM fluorescence_NN 
        in_IN situ_NN hybridization_NN ;_: LCM_NNP =_SYM laser_NN
        capture_NN microdissection_NN ;_: MADS_NNP =_SYM metastasis-associated_JJ DNA_NNP
        sequences_NNS ;_: NCBI_NNP =_SYM National_NNP Center_NNP for_IN Biotechnology_NNP
        Information_NNP ;_: PCR_NNP =_SYM polymerase_NN chain_NN reaction_NN ;_: RDA_NNP =_SYM
        representational_NN difference_NN analysis_NN ;_: SCM_NNP =_SYM single_JJ cell_NN
        microdissection_NN ;_: STS_NNP =_SYM sequence_NN tagged_VBN sites_NNS ._.
      
    
  
